Jesús Reviriego

1.8k total citations
70 papers, 1.4k citations indexed

About

Jesús Reviriego is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Physiology. According to data from OpenAlex, Jesús Reviriego has authored 70 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Endocrinology, Diabetes and Metabolism, 16 papers in Molecular Biology and 14 papers in Physiology. Recurrent topics in Jesús Reviriego's work include Diabetes Management and Research (38 papers), Diabetes Treatment and Management (34 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (13 papers). Jesús Reviriego is often cited by papers focused on Diabetes Management and Research (38 papers), Diabetes Treatment and Management (34 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (13 papers). Jesús Reviriego collaborates with scholars based in Spain, United States and Austria. Jesús Reviriego's co-authors include Ya‐Qing Lou, Leif Bertilsson, Keyi Wang, Lennart Iselius, Luis Alberto Vázquez, Tatiana Dilla, B. Augendre‐Ferrante, James Malone, Barbara N. Campaigne and Shuang Bai and has published in prestigious journals such as Diabetes Care, Brain Research and British Journal of Pharmacology.

In The Last Decade

Jesús Reviriego

69 papers receiving 1.3k citations

Peers

Jesús Reviriego
Anna Tavridou Greece
Stephen D. Wise Singapore
Kyoung Soo Lim South Korea
Prajakti A. Kothare United States
Walter Ziegler Switzerland
Lawrence E. Ramsay United Kingdom
Barbara Ameer United States
Malcolm A. Young United Kingdom
José Pablo Werba Italy
Francesco Rossi Italy
Anna Tavridou Greece
Jesús Reviriego
Citations per year, relative to Jesús Reviriego Jesús Reviriego (= 1×) peers Anna Tavridou

Countries citing papers authored by Jesús Reviriego

Since Specialization
Citations

This map shows the geographic impact of Jesús Reviriego's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jesús Reviriego with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jesús Reviriego more than expected).

Fields of papers citing papers by Jesús Reviriego

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jesús Reviriego. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jesús Reviriego. The network helps show where Jesús Reviriego may publish in the future.

Co-authorship network of co-authors of Jesús Reviriego

This figure shows the co-authorship network connecting the top 25 collaborators of Jesús Reviriego. A scholar is included among the top collaborators of Jesús Reviriego based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jesús Reviriego. Jesús Reviriego is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Duque, Natalia, Esther Artime, Irene Romera, et al.. (2021). Real-World Use of Insulin Glargine U100 and U300 in Insulin-Naïve Patients with Type 2 Diabetes Mellitus: DosInGlar Study. Advances in Therapy. 38(7). 3857–3871. 4 indexed citations
2.
Romera, Irene, Ignacio Conget, Luis Alberto Vázquez, et al.. (2020). Once-weekly dulaglutide versus insulin glargine in the early control of fasting serum glucose and HbA1c. Journal of Diabetes and its Complications. 34(7). 107575–107575. 3 indexed citations
3.
López‐Bastida, Julio, Juan Pedro López‐Siguero, Juan Oliva, et al.. (2019). Health-related quality of life in type 1 diabetes mellitus pediatric patients and their caregivers in Spain: an observational cross-sectional study. Current Medical Research and Opinion. 35(9). 1589–1595. 22 indexed citations
4.
Romera, Irene, Ana María Cebrián Cuenca, Fernando Álvarez Guisasola, Fernando Gómez‐Peralta, & Jesús Reviriego. (2018). A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes. Diabetes Therapy. 10(1). 5–19. 60 indexed citations
5.
López‐Bastida, Julio, Juan Pedro López‐Siguero, Juan Oliva, et al.. (2017). Social economic costs of type 1 diabetes mellitus in pediatric patients in Spain: CHRYSTAL observational study. Diabetes Research and Clinical Practice. 127. 59–69. 21 indexed citations
6.
7.
8.
Calvo‐Bonacho, Eva, et al.. (2013). Alta prevalencia de obesidad en una población laboral en España. Endocrinología y Nutrición. 60(4). 173–178. 9 indexed citations
9.
Dilla, Tatiana, Amparo Valladares, Claudia Nicolay, et al.. (2012). Healthcare Costs Associated with Change in Body Mass Index in Patients with Type 2 Diabetes Mellitus in Spain. Applied Health Economics and Health Policy. 10(6). 417–430. 27 indexed citations
10.
11.
Costi, Maria Paola, Helen T. Smith, Jesús Reviriego, et al.. (2011). Costes directos sanitarios en pacientes con diabetes mellitus tipo 2 a los seis meses de inicio del tratamiento con insulina en España: estudio INSTIGATE. Endocrinología y Nutrición. 58(6). 274–282. 12 indexed citations
12.
Polavieja, Pepa, et al.. (2010). Prevalencia del síndrome metabólico y grado de concordancia en su diagnóstico en pacientes con diabetes mellitus tipo 2 en España. Endocrinología y Nutrición. 57(2). 60–70. 7 indexed citations
13.
Costi, Maria Paola, Tatiana Dilla, Jesús Reviriego, Conxa Castell, & Albert Goday. (2009). Clinical characteristics of patients with type 2 diabetes mellitus at the time of insulin initiation: INSTIGATE observational study in Spain. Acta Diabetologica. 47(S1). 169–175. 31 indexed citations
14.
Reviriego, Jesús, Ramón Gomis, Juan P. Marañes, et al.. (2008). Cost of severe hypoglycaemia in patients with type 1 diabetes in Spain and the cost-effectiveness of insulin lispro compared with regular human insulin in preventing severe hypoglycaemia. International Journal of Clinical Practice. 62(7). 1026–1032. 22 indexed citations
15.
Dilla, Tatiana, Maria Paola Costi, Kristina S. Boye, et al.. (2008). El impacto de la obesidad en el manejo y evolución de la diabetes mellitus. Revista Clínica Española. 208(9). 437–443. 10 indexed citations
16.
Reviriego, Jesús, et al.. (2001). Calidad de vida en el tratamiento de la diabetes mellitus con insulina lispro y sus nuevas mezclas. Endocrinología y Nutrición. 48. 68–73. 1 indexed citations
17.
Reviriego, Jesús, et al.. (1996). Evaluation of the Diabetes Quality-of-Life Questionnaire in a Spanish Population. PharmacoEconomics. 10(6). 614–622. 22 indexed citations
18.
Reviriego, Jesús, et al.. (1993). Frequency of S-mephenytoin hydroxylation deficiency in 373 spanish subjects compared to other Caucasian populations. European Journal of Clinical Pharmacology. 44(6). 593–595. 12 indexed citations
19.
Bertilsson, Leif, et al.. (1992). Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clinical Pharmacology & Therapeutics. 51(4). 388–397. 328 indexed citations
20.
Reviriego, Jesús & Jesús Marı́n. (1989). Effects of 5‐hydroxytryptamine on human isolated placental chorionic arteries and veins. British Journal of Pharmacology. 96(4). 961–969. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anna Tavridou Breakdown of academic impact, for papers by Stephen D. Wise Breakdown of academic impact, for papers by Kyoung Soo Lim Breakdown of academic impact, for papers by Prajakti A. Kothare Breakdown of academic impact, for papers by Walter Ziegler Breakdown of academic impact, for papers by Lawrence E. Ramsay Breakdown of academic impact, for papers by Barbara Ameer Breakdown of academic impact, for papers by Malcolm A. Young Breakdown of academic impact, for papers by José Pablo Werba Breakdown of academic impact, for papers by Francesco Rossi
Rankless by CCL
2026